IM Cannabis (IMCC) Amortizatization of Intangibles (2020 - 2026)
IM Cannabis' (IMCC) quarterly Amortizatization of Intangibles came in at $272722.9 in Q1 2026, up 15.78% year-on-year from $235557.8 in Q1 2025, and up 11.7% quarter-over-quarter from $244149.4 in Q3 2025.
IM Cannabis (IMCC) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
IM Cannabis' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $272722.9 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles rose 15.78% year-over-year to $272722.9 in Q1 2026; TTM through Mar 2026 was $981212.9, a 8.16% increase from a year earlier, with the FY2024 full-year figure at $1.0 million, down 22.81% from the prior year.
- Amortizatization of Intangibles grew to $272722.9 in Q1 2026 per IMCC's latest filing, from $244149.4 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $508252.7 in Q2 2022 and bottomed at $195725.3 in Q3 2024.
- The 5-year median for Amortizatization of Intangibles is $318305.9 (2023), against an average of $318641.4.
- Across the five-year window, Amortizatization of Intangibles surged 1312.22% in 2022 and tumbled 39.12% in 2024, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $374981.8 in 2022, then dropped by 15.97% to $315115.7 in 2023, then retreated by 22.53% to $244104.6 in 2024, then rose by 0.02% to $244149.4 in 2025, then advanced by 11.7% to $272722.9 in 2026.
- Per Business Quant, the three latest IMCC Amortizatization of Intangibles figures stand at $272722.9 (Q1 2026), $244149.4 (Q3 2025), and $228782.9 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | IM Cannabis | 517,043.18 | -215,079.33 | 1.03 Mn | 272,722.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 272,722.93 |
| Mar 31, 2026 | 272,722.93 |
| Sep 30, 2025 | 244,149.36 |
| Sep 30, 2025 | 244,149.36 |
| Jun 30, 2025 | 228,782.86 |
| Jun 30, 2025 | 228,782.86 |
| Mar 31, 2025 | 235,557.77 |
| Mar 31, 2025 | 235,557.77 |
| Dec 31, 2024 | 244,104.56 |
| Dec 31, 2024 | 244,104.56 |
| Sep 30, 2024 | 195,725.26 |
| Sep 30, 2024 | 195,725.26 |
| Jun 30, 2024 | 231,771.55 |
| Jun 30, 2024 | 231,771.55 |
| Mar 31, 2024 | 335,435.17 |
| Mar 31, 2024 | 335,435.17 |
| Dec 31, 2023 | 315,115.74 |
| Dec 31, 2023 | 315,115.74 |
| Sep 30, 2023 | 321,496.03 |
| Sep 30, 2023 | 321,496.03 |